Sahebkar, Amirhossein <br/><br/>
New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect?  [electronic resource] 

 -  Cardiovascular drugs and therapy  Dec 2013 
 - 559-67 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1573-7241 
<br/><br/><label>Standard No.: </label>10.1007/s10557-013-6479-4  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Anticholesteremic Agents--therapeutic use<br/>Apolipoproteins B--metabolism<br/>Benzimidazoles--therapeutic use<br/>Cholesterol, LDL--metabolism<br/>Dyslipidemias--drug therapy<br/>Humans<br/>Lipid Metabolism, Inborn Errors--drug therapy<br/>Lipoprotein(a)--metabolism<br/>Oligonucleotides--therapeutic use<br/>Proprotein Convertase 9<br/>Proprotein Convertases--antagonists & inhibitors<br/>Serine Endopeptidases